Table 1.

Patient demographics and baseline characteristics

Voxelotor/placebo, mg/dMultiple dose for 28 dMultiple dose for 90 d
Placebo5007001000Placebo700900
N1010126466
Median age (range), y38 (21-53)29 (20-48)29 (20-56)40 (25-47)28 (18-48)41 (29-53)37 (25-42)
Male sex, n (%)6 (60)8 (80)4 (33)2 (33)3 (75)4 (67)3 (50)
Median BMI (range), kg/m223.5 (19.6-30.5)21.4 (17.2-27.5)23.0 (17.8-34.4)22.4 (20.2-26.1)18.8 (17.2-28.4)26.9 (21.9-35.3)22.8 (20.0-27.3)
Median baseline Hb (range), g/dL8.1 (7.2-10.0)7.9 (7.0-9.7)9.1 (7.5-9.8)8.2 (7.5-8.4)7.9 (7.2-9.3)8.3 (7.1-9.7)9.0 (7.6-9.7)
Hospitalizations due to painful crisis in the previous 12 mo, median (range)1 (0-7)0 (0-1)1 (0-7)1 (0-4)1 (0-2)0 (0-2)0 (0-1)
Patients with 0 events in previous 12 mo, n5753245
Blood transfusions in previous 12 mo, median (range)0 (0-1)0 (0)0 (0-4)0 (0-5)0 (0)0 (0)0 (0-1)
Current use of HU, n (%)3 (30)1 (10)3 (25)2 (33)1 (25)0 (0)2 (33)
  • BMI, body mass index; HU, hydroxyurea.